Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07).Fabrice André, Komal Jhaveri, Sherene Loi et al.|Journal of Clinical Oncology|2021Cited by 15